Background: In 21-hydroxylase deficiency (21-OHD), there is an influence of genotype on the severity of external genitalia virilization. However, females carrying mutations predicting a similar impairment of enzymatic activity present a wide variability of genital phenotypes. In such cases, interindividual variability in genes related to the sex steroid hormone pathway could play a role. Objective: To evaluate the influence of POR, HSD17B5 and SRD5A2 variants on the severity of external genitalia virilization in 21-OHD females. Design and Patients: Prader stages were evaluated in 178 females with 21-OHD from a multicenter study. The 21-OHD genotypes were divided into two groups according to their severity: severe and moderate. The influences of the POR p.A503V, HSD17B5 c.-71A>G, HSD17B5 c.-210A>C, and SRD5A2 p.A49T and p.V89L variants on the degree of external genitalia virilization were analyzed. Results: The POR p.A503V, HSD17B5 c.-71A>G, HSD17B5 c.-210A>C, and SRD5A2 p.A49T and p.V89L variants were found in 25, 33, 17, 1, and 31% of the alleles, respectively. In uni- and multilinear regression, HSD17B5 c.-210A>C has a significant influence on the degree of external genitalia virilization. This variant was also identified with a higher frequency in the most severely virilized females. Conclusion: We demonstrated that a variant in the promoter region of HSD17B5 related to fetal androgen synthesis influences the genital phenotype in 21-OHD females.

Keywords:
21-Hydroxylase deficiency, External genitalia virilization, Fetal androgen synthesis pathway, Allelic variants, 17β-Hydroxysteroid dehydrogenase type 5
1.
White PC, Speiser PW: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000;21:245-291.
2.
Finkielstain GP, Kim MS, Sinaii N, Nishitani M, Van Ryzin C, Hill SC, et al: Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2012;97:4429-4438.
3.
White PC, Bachega TA: Congenital adrenal hyperplasia due to 21 hydroxylase deficiency: from birth to adulthood. Semin Reprod Med 2012;30:400-409.
4.
Bachega TA, Billerbeck AE, Madureira G, Marcondes JA, Longui CA, Leite MV, et al: Molecular genotyping in Brazilian patients with the classical and nonclassical forms of 21-hydroxylase deficiency. J Clin Endocrinol Metab 1998;83:4416-4419.
5.
Witchel SF, Azziz R: Congenital adrenal hyperplasia. J Pediatr Adolesc Gynecol 2011;24:116-126.
6.
Kaupert LC, Lemos-Marini SH, De Mello MP, Moreira RP, Brito VN, Jorge AA, et al: The effect of fetal androgen metabolism-related gene variants on external genitalia virilization in congenital adrenal hyperplasia. Clin Genet 2013;84:482-488.
7.
Welzel M, Schwarz HP, Hedderich J, Dörr HG, Binder G, Brämswig JH, et al: No correlation between androgen receptor CAG and GGN repeat length and the degree of genital virilization in females with 21-hydroxylase deficiency. J Clin Endocrinol Metab 2010;95:2443-2450.
8.
Bachega TA, Billerbeck AE, Parente EB, Lemos-Marini SH, Baptista MT, Mello MP, et al: Multicentric study of Brazilian patients with 21-hydroxylase deficiency: a genotype-phenotype correlation (in Portuguese). Arq Bras Endocrinol Metabol 2004;48:697-704.
9.
Sugiyama Y, Mizuno H, Hayashi Y, Imamine H, Ito T, Kato I, et al: Severity of virilization of external genitalia in Japanese patients with salt-wasting 21-hydroxylase deficiency. Tohoku J Exp Med 2008;215:341-348.
10.
Goossens K, Juniarto AZ, Timmerman MA, Faradz SM, Wolffenbuttel KP, Drop SL, et al: Lack of correlation between phenotype and genotype in untreated 21-hydroxylase-deficient Indonesian patients. Clin Endocrinol (Oxf) 2009;71:628-635.
11.
Rocha RO, Billerbeck AE, Pinto EM, Melo KF, Lin CJ, Longui CA, et al: The degree of external genitalia virilization in girls with 21-hydroxylase deficiency appears to be influenced by the CAG repeats in the androgen receptor gene. Clin Endocrinol (Oxf) 2008;68:226-232.
12.
Miller WL: Minireview: regulation of steroidogenesis by electron transfer. Endocrinology 2005;146:2544-2550.
13.
Luu-The V, Dufort I, Pelletier G, Labrie F: Type 5 17β-hydroxysteroid dehydrogenase: its role in the formation of androgens in women. Mol Cell Endocrinol 2001;171:77-82.
14.
Kim KS, Liu W, Cunha GR, Russell DW, Huang H, Shapiro E, et al: Expression of the androgen receptor and 5α-reductase type 2 in the developing human fetal penis and urethra. Cell Tissue Res 2002;307:145-153.
15.
Bachega TA, Billerbeck AE, Madureira G, Arnhold IJ, Medeiros MA, Marcondes JA, et al: Low frequency of CYP2B deletions in Brazilian patients with congenital adrenal hyperplasia due to 21-hydroxylas deficiency. Hum Hered 1999;49:9-14.
16.
Paulino LC, Araujo M, Guerra G Jr, Marini SH, De Mello MP: Mutation distribution and CYP21/C4 locus variability in Brazilian families with the classical form of the 21-hydroxylase deficiency. Acta Paediatr 1999;88:275-283.
17.
Torres N, Mello MP, Germano CM, Elias LL, Moreira AC, Castro M: Phenotype and genotype correlation of the microconversion from the CYP21A1P to the CYP21A2 gene in congenital adrenal hyperplasia. Braz J Med Biol Res 2003;36:1311-1318.
18.
Speiser PW, Dupont J, Zhu D, Serrat J, Buegeleisen M, Tusie-Luna MT, et al: Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest 1992;90:584-595.
19.
Qin K, Ehrmann DA, Cox N, Refetoff S, Rosenfield RL: Identification of a functional polymorphism of the human type 5 17β-hydroxysteroid dehydrogenase gene associated with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:270-276.
20.
Li Z, Habuchi T, Mitsumori K, Kamoto T, Kinoshitu H, Segawa T, et al: Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population. J Urol 2003;169:2378-2381.
21.
Huang N, Agrawal V, Giacomini KM, Miller WL: Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci USA 2008;105:1733-1738.
22.
Zeigler-Johnson CM, Walker AH, Mancke B, Spangler E, Jalloh M, McBride S, et al: Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered 2002;54:13-21.
23.
Stikkelbroeck NM, Hoefsloot LH, de Wijs IJ, Otten BJ, Hermus AR, Sistermans EA: CYP21 gene mutation analysis in 198 patients with 21-hydroxylase deficiency in the Netherlands: six novel mutations and a specific cluster of four mutations. J Clin Endocrinol Metab 2003;88:3852-3859.
24.
Wilson RC, Nimkarn S, Dumic M, Obeid J, Azar MR, Najmabadi H, et al: Ethnic-specific distribution of mutations in 716 patients with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Mol Genet Metab 2007;90:414-421.
25.
Huang N, Pandey AV, Agrawal V, Reardon W, Lapunzina PD, Mowat D, et al: Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am J Hum Genet 2005;76:729-749.
26.
Gomes LG, Huang N, Agrawal V, Mendonca BB, Bachega TA, Miller WL: The common P450 oxidoreductase variant A503V is not a modifier gene for 21-hydroxylase deficiency. J Clin Endocrinol Metab 2008;93:2913-2916.
27.
Fernández-Cancio M, Audí L, Andaluz P, Torán N, Piró C, Albisu M, et al: SRD5A2 gene mutations and polymorphisms in Spanish 46,XY patients with a disorder of sex differentiation. Int J Androl 2011;34:e526-e535.
28.
Qin K, Rosenfield RL: Characterization of the basal promoter element of the human type 5 17β-hydroxysteroid dehydrogenase gene. Biochim Biophys Acta 2005;1728:115-125.
29.
Mojsin M, Stevanovic M: PBX1 and MEIS1 up-regulate SOX3 gene expression by direct interaction with a consensus binding site within the basal promoter region. Biochem J 2010;425:107-116.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.